Popular on Rezul
- The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
- Las Vegas Realtor Nancy Ruiz Earns Certified Luxury Home Marketing Specialist™ Designation
- Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
- The Jesse Roldan Team and Biz Hub Financial Successfully Facilitate One-Day Closing for Investor Deal in Hellertown, PA
- "We Don't Give a Crap About Interest Rates." Baby Boomers are Flexing Their Equity Muscles
- Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com
- Leadership Expert and Author Adam Holbrook Launches Breakthrough Book: Character Evolution
- Lake life awaits on Long Lake!
- Greenfield Communities Honored with Eight 2025 MAME Awards
- No Limits Method Revolutionizes Neurodivergent Education Through Embodied Cognition
Similar on Rezul
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Robert Michael & Co. Launches New Real Estate Website to Serve Central Florida Homebuyers and Sellers
- Remember Internet Pioneers NetCom Solutions & Network Solutions? Founder Emmit J. McHenry is Now Leading the Emerging Cybersecurity Firm Cycurion
- LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
Saol Therapeutics Announces Positive Topline Results from the SL-1002 RAISE Limb Spasticity Trial
Rezul News/10684281
~ Saol Therapeutics, a clinical-stage pharmaceutical company, has recently announced positive results from its SL-1002 RAISE Limb Spasticity Trial. The data was presented at the Spasticity X Symposium in Houston, Texas by Dr. Sheng Li and Dr. Gerard Francisco.
The trial focused on the safety and efficacy of SL-1002, a novel chemoneurolytic injection utilizing Saol's proprietary CYCLOPHLEX™ technology. It was a double-blind, vehicle-controlled study that included 32 patients with mild to severe limb spasticity. The primary endpoint was to evaluate the overall safety profile of SL-1002 compared to the vehicle.
The results showed that SL-1002 was well-tolerated with no therapy or program-limiting adverse events reported. Out of the 32 patients, 24 received SL-1002 while 8 received the vehicle. Five serious adverse events (SAEs) were reported but were determined by investigators to be unrelated to the treatment. Fourteen non-serious treatment-emergent adverse events (TEAEs) were observed and considered mild by investigators.
More on Rezul News
The secondary endpoints included assessments using the Modified Ashworth Scale (MAS), which is commonly used in spasticity trials. Despite not being powered for efficacy, SL-1002 showed a statistically significant improvement over the vehicle at multiple time points throughout the trial. At 6 months, there was a significant reduction in MAS compared to baseline in the SL-1002 arm (-1.18) compared to the vehicle arm (-0.33).
Dave Penake, CEO of Saol Therapeutics, expressed his excitement about these positive results and acknowledged the need for new treatment options for spasticity. He also highlighted the strong safety profile observed in this trial and the long-lasting efficacy of SL-1002.
Penake also thanked all those involved in making this trial possible, including patients, investigators, and clinical trial site teams. He emphasized their collaboration and commitment as the driving force behind medical progress.
More on Rezul News
Dr. Gerard Francisco, the Principal Investigator for the trial, commented on the urgent need for more innovative therapies to treat spasticity. He also noted that these early results show that SL-1002 is safe, effective, and durable.
The RAISE Limb Spasticity Trial was conducted at UTHealth Houston in Houston, TX, and the Medical College of Wisconsin in Milwaukee, WI. Saol Therapeutics plans to meet with the FDA in the first half of 2025 to determine the next steps for SL-1002 in its spasticity program.
In addition to limb spasticity, SL-1002 is also being investigated for its potential to treat pain related to osteoarthritis of the knee in the COMPASS Osteoarthritis Knee Pain Trial. Results from this trial are yet to be released.
Saol Therapeutics is dedicated to developing innovative treatments for debilitating conditions like spasticity and osteoarthritis. With these positive results from their RAISE Limb Spasticity Trial, they are one step closer to providing much-needed relief for patients suffering from these conditions.
The trial focused on the safety and efficacy of SL-1002, a novel chemoneurolytic injection utilizing Saol's proprietary CYCLOPHLEX™ technology. It was a double-blind, vehicle-controlled study that included 32 patients with mild to severe limb spasticity. The primary endpoint was to evaluate the overall safety profile of SL-1002 compared to the vehicle.
The results showed that SL-1002 was well-tolerated with no therapy or program-limiting adverse events reported. Out of the 32 patients, 24 received SL-1002 while 8 received the vehicle. Five serious adverse events (SAEs) were reported but were determined by investigators to be unrelated to the treatment. Fourteen non-serious treatment-emergent adverse events (TEAEs) were observed and considered mild by investigators.
More on Rezul News
- Cincinnati Real Estate Agent Promotes Homes To MORE Buyers For MORE Money
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Prime Retail/Office Space Available in West Allis
- Tova Capital Acquires Prominent Freestanding Retail Building in Santa Monica
The secondary endpoints included assessments using the Modified Ashworth Scale (MAS), which is commonly used in spasticity trials. Despite not being powered for efficacy, SL-1002 showed a statistically significant improvement over the vehicle at multiple time points throughout the trial. At 6 months, there was a significant reduction in MAS compared to baseline in the SL-1002 arm (-1.18) compared to the vehicle arm (-0.33).
Dave Penake, CEO of Saol Therapeutics, expressed his excitement about these positive results and acknowledged the need for new treatment options for spasticity. He also highlighted the strong safety profile observed in this trial and the long-lasting efficacy of SL-1002.
Penake also thanked all those involved in making this trial possible, including patients, investigators, and clinical trial site teams. He emphasized their collaboration and commitment as the driving force behind medical progress.
More on Rezul News
- Employee Relocation Trends: North American Van Lines Launches New White Paper
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Corner Property Management Appointed Managing Agent for Minneakoning Business Center in Flemington
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
Dr. Gerard Francisco, the Principal Investigator for the trial, commented on the urgent need for more innovative therapies to treat spasticity. He also noted that these early results show that SL-1002 is safe, effective, and durable.
The RAISE Limb Spasticity Trial was conducted at UTHealth Houston in Houston, TX, and the Medical College of Wisconsin in Milwaukee, WI. Saol Therapeutics plans to meet with the FDA in the first half of 2025 to determine the next steps for SL-1002 in its spasticity program.
In addition to limb spasticity, SL-1002 is also being investigated for its potential to treat pain related to osteoarthritis of the knee in the COMPASS Osteoarthritis Knee Pain Trial. Results from this trial are yet to be released.
Saol Therapeutics is dedicated to developing innovative treatments for debilitating conditions like spasticity and osteoarthritis. With these positive results from their RAISE Limb Spasticity Trial, they are one step closer to providing much-needed relief for patients suffering from these conditions.
Filed Under: Business
0 Comments
Latest on Rezul News
- csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
- Advantages of Working With a Top-Producing Property Management Team
- Advantages of Working With The Top Producing Realtor®
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- Corner Property Management Now Managing Van Wagenen Terrace COA in Jersey City, NJ
- Svn Chicago Property Management Acquires Edgemark Asset Management's Property Management Division
- Maurer Painting Helps Home Sellers Maximize Their Property's Value with Pre-Sale Painting Services
- Mizner Country Club Establishes Mizner University
- David Weekley Homes Set to Open Paulding County's Old Mill Preserve in June
- Let's Talk Series: At the Crossroads: Immigration Today
- Occupier Secures $16 Million Growth Investment from Unbundled Capital to Expand Product Innovation and Accelerate Go-To-Market Strategy
- Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
- DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
- Innovative Management Expands into Northern Kentucky, Delivering Localized HOA Expertise
- Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
- Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
- Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings
- Emerge Apps Launches Mod Performance Suite: A New Era of Work Comp Selling for Insurance Agents